Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

证券日报网讯 9月19日晚间，诚达药业发布公告称，本次保荐代表人更换后，公司首次公开发行股票并 在创业板上市项目的持续督导保荐代表人为杨科先生、韩剑龙先生。 （文章来源：证券日报） ...

诚达药业股份有限公司（以下简称"公司"）于近日收到公司保荐机构光 大证券股份有限公司（以下简称"光大证券"）出具的《关于更换诚达药业股份 有限公司保荐代表人的报告》，保荐代表人范国祖先生因工作变动原因，不再负 责公司首次公开发行股票并在创业板上市的持续督导工作。为保证持续督导工作 的有序进行，光大证券决定由韩剑龙先生（简历详见附件）接替范国祖先生的持 续督导工作，继续履行督导职责。 本次保荐代表人更换后，公司首次公开发行股票并在创业板上市项目的持续 督导保荐代表人为杨科先生、韩剑龙先生。公司首次公开发行股票并在创业板上 市的持续督导期将于 2025 年 12 月 31 日到期。届时如公司募集资金尚未使用完 毕，光大证券对募集资金使用情况将继续履行持续督导义务。持续督导期限至持 续督导义务结束之日止。 公司董事会对范国祖先生在公司首次公开发行股票并在创业板上市的持续 督导期间所作的工作表示衷心感谢！ 特此公告。 诚达药业股份有限公司董事会 2025 年 9 月 19 日 附件：韩剑龙先生简历 证券代码：301201 证券简称：诚达药业 公告编号：2025-034 诚达药业股份有限公司 关于更换持续督导保荐代表人 ...

Core Viewpoint - L-Carnitine is increasingly recognized as a crucial "conditional nutrient" that aids in fat metabolism and energy production, leading to a growing demand in the health and fitness market [1][4][11] Industry Definition and Production Process - L-Carnitine is a naturally occurring amino acid that transports long-chain fatty acids into mitochondria for energy production, playing a vital role in energy metabolism [2][3] - The main production methods include direct extraction, chemical synthesis, enzymatic conversion, and bacterial fermentation [3][6] Current Industry Status - The demand for L-Carnitine in China is projected to grow from 1,343 tons in 2018 to 3,171 tons in 2024, with the market size increasing from 21.165 billion yuan to 39.060 million yuan [5] - China has become the largest producer and exporter of L-Carnitine globally, with production expected to reach 10,043 tons and exports to 6,872 tons in 2024 [5][6] Industry Supply Chain - Early production methods relied on animal sources, which were inefficient and costly, leading to the adoption of more effective methods [6] - L-Carnitine can be synthesized in the body but is often supplemented in specific populations such as athletes, vegetarians, and the elderly [6] Competitive Landscape - Major players in the Chinese L-Carnitine market include Guangzhou Longsha Pharmaceutical Co., Northeast Pharmaceutical Group, and Chengda Pharmaceutical Co., with Chengda being the largest producer [7][9] - Chengda Pharmaceutical's production capacity is around 4,000 tons annually, making it a significant global supplier [9] Industry Development Trends - The market for L-Carnitine is expected to grow steadily due to increasing health awareness and an aging population [11] - Future trends indicate a diversification of L-Carnitine products to cater to personalized health management and a broader range of applications [11]

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

| （1）是否存在需要关注的事项 | 是 2025 年 1-6 月，公司实现营业收入 | | --- | --- | | | 18,245.30 万 元 ， 较 上 年 同 期 增 长 | | | 11.24%；归属于上市公司股东的净利 | | | 润 万元，较上年同期下降 1,282.44 | | | 49.06%；归属于上市公司股东的扣除 | | （2）关注事项的主要内容 | 非经常性损益后的净利润 万 289.90 | | | 元，较上年同期下降 8.37%。 | | | 公司净利润较上年同期下降，主要 | | | 由于公司募投项目工程交付新增折旧 | | | 导致管理费用增加，以及报告期内投 | | | 资收益下降等原因所致。 | | | 保荐机构将持续关注上市公司的 | | （3）关注事项的进展或者整改情况 | 业绩情况，并督导上市公司按照相关 | | | 法律法规履行信息披露义务。 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 0 次，拟下半年开展培训 | | （2）培训日期 | 不适用 | | （3）培训的主要内容 | ...

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is experiencing poor performance, leading to continuous share reductions by original shareholders, particularly Shenzhen Qianhai Shengtai Investment Enterprise, which plans to sell up to 11 million shares, potentially cashing out 316 million yuan [1][3][9]. Group 1: Shareholder Actions - Shenzhen Qianhai Shengtai plans to reduce its holdings by up to 11 million shares, representing 7.27% of the company's total shares, within three months starting from September 29, 2025 [2][3]. - Over the past two and a half years, Qianhai Shengtai has reduced its holdings in Chengda Pharmaceutical, cashing out a total of 634 million yuan [1][9]. - The latest reduction plan follows a series of previous reductions, with Qianhai Shengtai having already cashed out 318 million yuan from earlier sales [8][9]. Group 2: Company Performance - For the first half of 2025, Chengda Pharmaceutical reported revenue of 182 million yuan, an increase of 11.24% year-on-year, but net profit fell by 49.06% to 12.82 million yuan [11][12]. - The company's stock price has dropped over 60% from its initial public offering price of 72.69 yuan, with the current price at 28.74 yuan [9][10]. - Chengda Pharmaceutical's revenue and net profit have shown a declining trend over the past few years, with a notable loss of 28.1 million yuan in 2024, marking the first loss since 2010 [12][13]. Group 3: Business Challenges - The decline in revenue is attributed to a 33.22% drop in sales of raw materials, particularly due to clients overstocking in anticipation of national centralized procurement [12][13]. - The CDMO (Contract Development and Manufacturing Organization) segment also faced a 37.65% decline in sales due to increased competition and global economic uncertainties [12][13]. - Chengda Pharmaceutical aims to expand its market presence and enhance its brand value through various promotional activities and by deepening relationships with existing clients [13].

Key Points - Western Gold's main business includes gold mining and smelting [1] - Donghu Gaoxin's subsidiary plans to establish a joint venture for the Changzi waste incineration project [1] - Southeast Network Framework won a 1.32 billion yuan EPC project as part of a consortium [1] - New Fengming intends to acquire 100% of Samir for 102 million yuan [1] - Lingzhi Software completed the second phase of share repurchase, totaling 0.9375% of its shares [1][2] - New Hope reported 1.722 billion yuan in pig sales revenue for August [1][2] - Muyuan Foods reported 11.85 billion yuan in pig sales revenue for August [1][2] - Shareholders of Chengda Street Industry plan to reduce their holdings by no more than 7.27% [1][3] - ST Lingnan received a notice from the Securities Regulatory Commission regarding suspected information disclosure violations [1][3]

Summary of Key Points Core Viewpoint - On September 5, Guizhou Moutai disclosed its shareholding increase, while 24 listed companies announced shareholding reductions, indicating a mixed sentiment in the market regarding stock performance and investor confidence [1][2]. Group 1: Shareholding Increases - Guizhou Moutai's controlling shareholder, Moutai Group, received a commitment letter for a loan of up to 2.7 billion yuan from Agricultural Bank [2]. Group 2: Shareholding Reductions - A total of 24 companies reported shareholding reductions, including: - Aohai Technology: Shareholder plans to reduce holdings by up to 7 million shares [2]. - Ruihu Mould: Shareholder plans to reduce up to 3% of company shares [2]. - Guanghua Technology: Some executives plan to reduce a total of up to 477.81 thousand shares [2]. - Kaipu Detection: Vice President plans to reduce company shares [2]. - Liren Technology: Controlling shareholder plans to reduce up to 3% of shares [2]. - Tonghuashun: Controlling shareholder plans to reduce a total of up to 0.26% of shares [2]. - Kexin Innovation Source: One of the actual controllers plans to reduce up to 141.5 thousand shares [2]. - Other companies such as Feima International, Changjiang Materials, and others also reported various plans for share reductions [2].

Key Points - China Petroleum & Chemical Corporation (Sinopec) announced a cash dividend of RMB 0.088 per share, totaling RMB 10.662 billion [4] - Guokai Microelectronics is progressing with a share issuance and cash payment to acquire 94.366% of the equity in Zhongxin Integrated Circuit (Ningbo) Co., Ltd. [5][6] - Phoenix Shipping's Vice General Manager Zhao Qiuling resigned due to work adjustments, while Wang Guozheng was appointed as the new financial director [7] - Guokai Co., Ltd. changed its stock abbreviation to Guokai Electronics, effective September 11, 2025 [8] - Xinhua Pharmaceutical's Vice General Manager Zheng Zhonghui resigned for personal reasons, holding 397,600 shares [9] - Uni-President's controlling shareholder's equity structure change was completed, transferring shares from the Ministry of Finance to Central Huijin Investment [10] - ST New Power may face delisting risk due to a negative audit opinion on its internal controls [11] - Huachuang Yuxin announced that 1.87% of its shares held by Shanghai Shiran Industrial Co., Ltd. will be auctioned [12][13] - Zhengbang Technology's subsidiary was accepted for reorganization by the court due to financial difficulties [14] - China Shipbuilding Defense's General Manager Chen Liping resigned due to work changes [15] - ST Lingnan and its former controlling shareholder are under investigation for information disclosure violations [16] - Hikvision's chairman proposed a mid-term dividend of RMB 4 per 10 shares, amounting to RMB 3.666 billion [17] - Huada Jiutian's shareholder plans to transfer 2.64% of the company's shares [18] - Poly Developments reported a signing amount of RMB 18.015 billion in August, a year-on-year decrease of 18.54% [19] - Muyuan Foods reported a revenue of RMB 11.85 billion from selling 7.001 million pigs in August, a year-on-year decrease of 12.30% [20] - Dongrui Co., Ltd. reported a revenue of RMB 160 million from selling 94,800 pigs in August, a month-on-month decrease of 5.48% [21] - Ankai Bus reported a cumulative production increase of 68.06% year-on-year [22] - Kweichow Moutai's controlling shareholder received a loan commitment of up to RMB 2.7 billion for stock repurchase [23] - Chengda Pharmaceutical's major shareholder plans to reduce its stake by 7.27% [24][25] - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 3% [26] - Koweil plans to reduce its stake by up to 2.34% [27] - Funeng Technology's shareholders plan to reduce their stake by up to 2% [28] - United Water's shareholder plans to reduce its stake by 3% [29] - Huayin Power's shareholder plans to reduce its stake by 1% [30] - Tianji Co., Ltd. reported a reduction of 0.61% in its controlling shareholder's stake [31] - Tonghuashun's controlling shareholder plans to reduce its stake by up to 138,310 shares [32] - JA Solar has not yet started its share repurchase plan [33] - Beite Technology plans to raise no more than RMB 300 million through a private placement [34] - Aerospace Hongtu signed a strategic cooperation agreement with Pakistan worth RMB 2.9 billion, which is still in preliminary stages [35][36] - Guangqi Technology signed contracts for mass production of metamaterials worth RMB 1.278 billion [37]